Clinical impact of PSMA-based 18F-DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy.

Esther MenaMaria L LindenbergJoanna H ShihStephen AdlerStephanie HarmonEthan BergvallDeborah CitrinWilliam DahutAnita T TonYolanda McKinneyJuanita WeaverPhilip EclarinalAlicia ForestGeorge AfariSibaprasad BhattacharyyaRonnie C MeaseMaria J MerinoPeter PintoBradford J WoodPaula JacobsMartin G PomperPeter L ChoykeBaris Turkbey

Published in: European journal of nuclear medicine and molecular imaging (2017)

18F-DCFBC detects recurrences in 60.3% of a population of patients with biochemical recurrence, but results are dependent on PSA levels. Above a threshold PSA value of 0.78 ng/mL, 18F-DCFBC was able to identify recurrence with high reliability. Positive 18F-DCFBC PET imaging led clinicians to change treatment strategy in 51.2% of patients.

Keyphrases

pet ct
prostate cancer
pet imaging
radical prostatectomy
positron emission tomography
end stage renal disease
ejection fraction
chronic kidney disease
high resolution
newly diagnosed
palliative care
peritoneal dialysis
prognostic factors
computed tomography
free survival
stem cells
bone marrow
replacement therapy